Amgen sales and earnings beat analysts' estimates
Amgen (Nasdaq: AMGN) yesterday released financial results for the second quarter of 2018 that beat expectations, and pushed the firm’s share up 1.06% to $196.11 in after-hours trading.
The company posted revenue of $6.06 billion, up 4.3% on the like 2017 quarter, exceeding Wall Street forecasts. Eight analysts surveyed by Zacks Investment expected $5.72 billion.
Second-quarter net income on a generally accepted accounting principles (GAAP) basis was $2.3 billion, a rise of 7%. Earnings per share (EPS) came in at $3.48, up 20%. Earnings, adjusted for non-recurring costs, were $3.83 per share, up 17.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze